PLC (NASDAQ: TCBP), a biotechnology firm with a market capitalization of $33.08 million engaged in developing gamma-delta T cell therapies, announced today significant progress in its ACHIEVE Phase 2B ...
Immune cells in the bone marrow microenvironment of AML patients are key in distinguishing a response to immunotherapy.
TC BioPharm (TCBP) announced the first Cohort B patient in the ACHIEVE Phase 2B UK clinical trial, evaluating TCB008 in Acute Myeloid Leukemia, ...
TC BioPharm's Phase 2B trial of TCB008 in AML progresses as the first Cohort B patient completes dosing. Enrollment continues, with data expected in 2025.
Mikkael A. Sekeres, MD, Sylvester Comprehensive Cancer Center, discusses the potential benefits of treosulfan, a newly ...
Galinpepimut-S therapy showed specific T-Cell immune responses for patients with acute myeloid leukemia in remission ...
If Maggie O'Neil can't find a match among family members, she'll have to turn to a global nonprofit that connects volunteer ...
Leukemic stem cells (LSCs) and stemness signatures contribute to minimal residual disease in patients with acute myeloid ...
Orca Bio announces it met the primary endpoint in its pivotal Phase 3 clinical study for its lead allogeneic T-cell immunotherapy, Orca-T.
Kura and Kyowa used the announcement to confirm that they are on track to file a new drug approval application with the FDA ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback